Conformationally Sensitive Antibodies for Integrin Ligand Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting integrin ligands and modulating their activity are limited in efficiency and specificity, particularly in identifying allosteric antagonists for integrins like VLA-4, which are crucial for treating inflammatory and immune-related diseases.
Innovation Solution
A method utilizing ligand-induced epitopes and conformationally sensitive antibodies to detect and quantify integrin ligands, allowing for the identification of competitive and allosteric modulators through flow cytometry-based assays, including the use of Prestwick Chemical Library screening to identify VLA-4 allosteric antagonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to detect integrin ligands, then the assay can be performed with simple equipment, but the measurement precision and specificity are insufficient
Solution Approach 1:
The patent employs conformationally sensitive antibodies as intermediary molecules that indirectly detect integrin ligand binding. These antibodies bind to epitopes on the integrin that are exposed only when the integrin is in a ligand-bound conformation, providing a reliable indirect measurement of ligand affinity without requiring direct ligand detection or complex labeling procedures
Solution Approach 2:
The patent utilizes flow cytometry-based detection that measures changes in fluorescence signal intensity. Conformationally sensitive antibodies are labeled with fluorescent markers, and the fluorescence signal intensity correlates with the degree of integrin activation and ligand binding, enabling quantitative measurement of ligand affinity through optical detection
2Measurement precision
If the assay is designed to detect ligand binding affinity, then measurement precision improves, but the ease of operation decreases
Solution Approach 1:
The integrin itself serves as the detector by undergoing conformational changes that automatically expose epitopes when bound to ligands. The system uses the integrin's own conformational dynamics to generate the detection signal, eliminating the need for separate sensing components or complex signal generation mechanisms
Solution Approach 2:
The conformationally sensitive antibodies are pre-selected and characterized to specifically recognize epitopes that are exposed only in the activated integrin conformation. This preliminary selection ensures that the assay automatically distinguishes between bound and unbound states without requiring additional processing steps
3Measurement precision
If the method uses conformationally sensitive antibodies to detect ligand-induced epitopes, then measurement precision and specificity improve, but the device complexity increases
Solution Approach 1:
The flow cytometry platform is used for multiple purposes: it quantifies integrin expression levels, detects conformational changes through epitope exposure, and measures ligand binding affinity all within the same instrument and assay format, eliminating the need for separate specialized equipment for each function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the precise identification and characterization of integrin modulators, including VLA-4 allosteric antagonists, which can effectively block VLA-4/VCAM-1 dependent cell adhesion and induce immunosuppressive effects, providing a plausible mechanism for the therapeutic action of identified compounds.
Implementation Method 1
Conformational changes can be detected using conformationally sensitive antibodies, which bind to defined epitopes exposed only in certain molecular conformations. Some of these are known to be induced by the binding of the ligand (so called ligand induced binding sites (LIBS)).
Implementation Method 2
epitope exposure represents a valuable tool for monitoring integrin conformations using flow cytometery techniques
Data Source
AI summary
This invention relates generally to integrin ligand discovery and to a method of integrin ligand discovery base upon induction of ligand-induced epitopes. Such ligands have the potential to be active agent as anti-inflammatory, anti-angiogenesis and/or anti-thrombotic agents and for the treatment of integrin mediated diseases and/or conditions.